Yi Xiao
Pacific Northwest National Laboratory
ORCID: 0000-0002-1389-3106Also affiliated with Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing General Hospital of Nanjing Military Command, Government of the United States of America, Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, First Hospital of Lanzhou University, Chengdu University of Traditional Chinese Medicine, University of Nebraska Medical Center, Lanzhou University, Nanjing Medical University, Nanjing University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 9 papers. Top paper: “Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial”.
Zhong-Hua Wang, Lin-Xiaoxi Ma, Song-Yang Wu, Jiong Wu, Ke-Da Yu +23 more
Yuanhong Chen, Aimin Peng, Jixin Dong, Yi Xiao
Henry C.-H. Law, Kimiko L. Krieger, Emalie J. Clement, Yi Xiao, Shannon M. Buckley +2 more
Ling Yin, Jiuli Zhou, Renya Zeng, Yi Xiao, Adrian R. Black +8 more
Jixin Dong, Yi Xiao
Yuanhong Chen, Jianan Chen, Jixin Dong, Yi Xiao
Olawale A. Alimi, Yanfei Wang, Yunfan Kong, Mitchell Kuss, Mena Asha Krishnan +6 more
Yi Xiao, Yuanhong Chen, Jixin Dong, Karthik Balakrishnan
Jixin Dong, Yi Xiao